Dr James Musick is VP and head of digital transformation at UCB Biopharma where he is responsible for helping UCB improve lives of people living with severe disease by applying new digital ...

In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...

Biogen and UCB on Tuesday shared an expanded dataset for their Phase 3 lupus program, which they said two months ago ...

The U.S. FDA added hidradenitis suppurativa to the label for UCB SA’s Bimzelx (bimekizumab-bkzx), throwing renewed light on the indication, a chronic disease that causes painful, boil-like lumps that ...

UCB recently partnered with the CDD on two candidates. The Belgian biopharma company approached the CDD and, after working through the review process, reached an agreement that gives the CDD a ...

Begin your TipRanks Premium journey today. UCB SA (0NZT) Company Description: UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous ...